CN101554368A - 一种室温稳定的注射用替曲朵辛组合物制剂 - Google Patents
一种室温稳定的注射用替曲朵辛组合物制剂 Download PDFInfo
- Publication number
- CN101554368A CN101554368A CN 200810088914 CN200810088914A CN101554368A CN 101554368 A CN101554368 A CN 101554368A CN 200810088914 CN200810088914 CN 200810088914 CN 200810088914 A CN200810088914 A CN 200810088914A CN 101554368 A CN101554368 A CN 101554368A
- Authority
- CN
- China
- Prior art keywords
- tetradoxin
- injection
- preparation
- acid
- temp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002347 injection Methods 0.000 title claims abstract description 65
- 239000007924 injection Substances 0.000 title claims abstract description 65
- 239000000203 mixture Substances 0.000 title claims abstract description 36
- 238000009472 formulation Methods 0.000 title claims abstract description 15
- CFMYXEVWODSLAX-QOZOJKKESA-N tetrodotoxin Chemical compound O([C@@]([C@H]1O)(O)O[C@H]2[C@@]3(O)CO)[C@H]3[C@@H](O)[C@]11[C@H]2[C@@H](O)N=C(N)N1 CFMYXEVWODSLAX-QOZOJKKESA-N 0.000 title claims abstract description 13
- CFMYXEVWODSLAX-UHFFFAOYSA-N tetrodotoxin Natural products C12C(O)NC(=N)NC2(C2O)C(O)C3C(CO)(O)C1OC2(O)O3 CFMYXEVWODSLAX-UHFFFAOYSA-N 0.000 title claims abstract description 13
- 229950010357 tetrodotoxin Drugs 0.000 title claims abstract description 13
- 238000002360 preparation method Methods 0.000 claims abstract description 75
- 239000003814 drug Substances 0.000 claims abstract description 36
- 150000007524 organic acids Chemical class 0.000 claims abstract description 29
- 239000000243 solution Substances 0.000 claims abstract description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 126
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 51
- 229930195725 Mannitol Natural products 0.000 claims description 51
- 239000000594 mannitol Substances 0.000 claims description 51
- 235000010355 mannitol Nutrition 0.000 claims description 51
- 239000000872 buffer Substances 0.000 claims description 39
- 239000001509 sodium citrate Substances 0.000 claims description 30
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 30
- 231100000765 toxin Toxicity 0.000 claims description 30
- 239000003053 toxin Substances 0.000 claims description 29
- 241000054452 Takifugu ocellatus Species 0.000 claims description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 27
- 239000008215 water for injection Substances 0.000 claims description 26
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 19
- 229940079593 drug Drugs 0.000 claims description 19
- 239000008101 lactose Substances 0.000 claims description 19
- 235000001014 amino acid Nutrition 0.000 claims description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 15
- 150000001413 amino acids Chemical class 0.000 claims description 15
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 14
- 239000000843 powder Substances 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 12
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 235000000346 sugar Nutrition 0.000 claims description 11
- STNXQECXKDMLJK-NLWUVLGBSA-N anhydroepitetrodotoxin Chemical compound C12C([C@@]3(O)CO)O[C@@]4(O)[C@H]5OC2N=C(N)N[C@@]15[C@H](O)[C@@H]3O4 STNXQECXKDMLJK-NLWUVLGBSA-N 0.000 claims description 10
- 239000002131 composite material Substances 0.000 claims description 10
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 claims description 8
- CKLJMWTZIZZHCS-UHFFFAOYSA-N Aspartic acid Chemical compound OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 claims description 8
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 8
- 238000004821 distillation Methods 0.000 claims description 8
- 150000002596 lactones Chemical class 0.000 claims description 8
- 239000005715 Fructose Substances 0.000 claims description 7
- 229930091371 Fructose Natural products 0.000 claims description 7
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 7
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 7
- 241000282414 Homo sapiens Species 0.000 claims description 7
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 7
- 239000003708 ampul Substances 0.000 claims description 7
- 239000004220 glutamic acid Substances 0.000 claims description 7
- 235000013922 glutamic acid Nutrition 0.000 claims description 7
- 241001597008 Nomeidae Species 0.000 claims description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 6
- MWPMJZZQPDXVJT-UHFFFAOYSA-N Tetrodonic acid Natural products N1C(N)=NC2OC(C(O)=O)C31C2C(O)C(O)(CO)C(O)C3O MWPMJZZQPDXVJT-UHFFFAOYSA-N 0.000 claims description 6
- 150000001720 carbohydrates Chemical class 0.000 claims description 6
- 235000015165 citric acid Nutrition 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 6
- MWPMJZZQPDXVJT-JTUKEBEQSA-N tetrodonicacid Chemical compound [C@]12([C@H](C(O)=O)O[C@@H]3N=C(N1)N)[C@@H]3[C@@H](O)[C@@](O)(CO)[C@H](O)[C@@H]2O MWPMJZZQPDXVJT-JTUKEBEQSA-N 0.000 claims description 6
- 108010001394 Disaccharidases Proteins 0.000 claims description 5
- 235000003704 aspartic acid Nutrition 0.000 claims description 5
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 238000004108 freeze drying Methods 0.000 claims description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 4
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 4
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 4
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 4
- 239000004327 boric acid Substances 0.000 claims description 4
- 238000011049 filling Methods 0.000 claims description 4
- 150000004676 glycans Chemical class 0.000 claims description 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 4
- 239000008363 phosphate buffer Substances 0.000 claims description 4
- 229920001282 polysaccharide Polymers 0.000 claims description 4
- 239000005017 polysaccharide Substances 0.000 claims description 4
- HELHAJAZNSDZJO-OLXYHTOASA-L sodium L-tartrate Chemical compound [Na+].[Na+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O HELHAJAZNSDZJO-OLXYHTOASA-L 0.000 claims description 4
- 239000001632 sodium acetate Substances 0.000 claims description 4
- 235000017281 sodium acetate Nutrition 0.000 claims description 4
- 239000001433 sodium tartrate Substances 0.000 claims description 4
- 229960002167 sodium tartrate Drugs 0.000 claims description 4
- 235000011004 sodium tartrates Nutrition 0.000 claims description 4
- 239000011975 tartaric acid Substances 0.000 claims description 4
- 235000002906 tartaric acid Nutrition 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 230000036592 analgesia Effects 0.000 claims description 3
- 230000003115 biocidal effect Effects 0.000 claims description 3
- 235000010338 boric acid Nutrition 0.000 claims description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 3
- 235000017550 sodium carbonate Nutrition 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- 206010002091 Anaesthesia Diseases 0.000 claims description 2
- 206010012335 Dependence Diseases 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims description 2
- 230000037005 anaesthesia Effects 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 229940088710 antibiotic agent Drugs 0.000 claims description 2
- 238000009360 aquaculture Methods 0.000 claims description 2
- 244000144974 aquaculture Species 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 235000014633 carbohydrates Nutrition 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 206010013663 drug dependence Diseases 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 238000010255 intramuscular injection Methods 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 235000011083 sodium citrates Nutrition 0.000 claims description 2
- 208000011117 substance-related disease Diseases 0.000 claims description 2
- FBZSEUKHTGSGBE-UHFFFAOYSA-L C([O-])([O-])=O.[Na+].C(C(O)C(O)C(=O)O)(=O)O.[Na+] Chemical compound C([O-])([O-])=O.[Na+].C(C(O)C(O)C(=O)O)(=O)O.[Na+] FBZSEUKHTGSGBE-UHFFFAOYSA-L 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007853 buffer solution Substances 0.000 abstract description 10
- 238000004519 manufacturing process Methods 0.000 abstract description 8
- 238000000034 method Methods 0.000 abstract description 6
- 239000000463 material Substances 0.000 abstract 1
- 238000002156 mixing Methods 0.000 abstract 1
- 238000003756 stirring Methods 0.000 description 22
- CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 16
- 238000004128 high performance liquid chromatography Methods 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- 229910052799 carbon Inorganic materials 0.000 description 12
- 238000010812 external standard method Methods 0.000 description 11
- 239000012528 membrane Substances 0.000 description 11
- 238000005374 membrane filtration Methods 0.000 description 11
- 238000012856 packing Methods 0.000 description 11
- 159000000000 sodium salts Chemical class 0.000 description 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 10
- 239000002671 adjuvant Substances 0.000 description 10
- 229940024606 amino acid Drugs 0.000 description 10
- 238000004321 preservation Methods 0.000 description 9
- 229960005261 aspartic acid Drugs 0.000 description 8
- 230000007774 longterm Effects 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
- 239000008176 lyophilized powder Substances 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 238000006345 epimerization reaction Methods 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 239000003381 stabilizer Substances 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 241001441728 Molidae Species 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 241001441723 Takifugu Species 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000006184 cosolvent Substances 0.000 description 3
- 238000005906 dihydroxylation reaction Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 125000004430 oxygen atom Chemical group O* 0.000 description 3
- GXFZCDMWGMFGFL-KKXMJGKMSA-N (+)-Tubocurarine chloride hydrochloride Chemical compound [Cl-].[Cl-].C([C@H]1[N+](C)(C)CCC=2C=C(C(=C(OC3=CC=C(C=C3)C[C@H]3C=4C=C(C(=CC=4CC[NH+]3C)OC)O3)C=21)O)OC)C1=CC=C(O)C3=C1 GXFZCDMWGMFGFL-KKXMJGKMSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 241001111317 Chondrodendron tomentosum Species 0.000 description 2
- 241000195493 Cryptophyta Species 0.000 description 2
- 239000008709 Curare Substances 0.000 description 2
- 241000371997 Eriocheir sinensis Species 0.000 description 2
- 241000237858 Gastropoda Species 0.000 description 2
- 241001417103 Gyrinocheilidae Species 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 241000238413 Octopus Species 0.000 description 2
- 241000736919 Pelodiscus sinensis Species 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000003186 pharmaceutical solution Substances 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 235000015170 shellfish Nutrition 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- GPJHMNRISIUJTD-UHFFFAOYSA-N 2-amino-6-(hydroxymethyl)quinazolin-8-ol Chemical compound C1=C(CO)C=C(O)C2=NC(N)=NC=C21 GPJHMNRISIUJTD-UHFFFAOYSA-N 0.000 description 1
- SNBAZGAHVJGFDT-UHFFFAOYSA-N 6-methylquinazolin-2-amine Chemical compound N1=C(N)N=CC2=CC(C)=CC=C21 SNBAZGAHVJGFDT-UHFFFAOYSA-N 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 101710138657 Neurotoxin Proteins 0.000 description 1
- 241001441724 Tetraodontidae Species 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- -1 amino hydrogenated quinazoline oxazoline compound Chemical class 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N anhydrous guanidine Natural products NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000037191 muscle physiology Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- 231100000618 neurotoxin Toxicity 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 235000012976 tarts Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200810088914 CN101554368B (zh) | 2008-04-07 | 2008-04-07 | 一种室温稳定的注射用替曲朵辛组合物制剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200810088914 CN101554368B (zh) | 2008-04-07 | 2008-04-07 | 一种室温稳定的注射用替曲朵辛组合物制剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101554368A true CN101554368A (zh) | 2009-10-14 |
CN101554368B CN101554368B (zh) | 2013-06-12 |
Family
ID=41172750
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200810088914 Expired - Fee Related CN101554368B (zh) | 2008-04-07 | 2008-04-07 | 一种室温稳定的注射用替曲朵辛组合物制剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101554368B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107468646A (zh) * | 2017-08-22 | 2017-12-15 | 新乡医学院第附属医院 | 氨磷汀注射液在治疗小儿血小板减少性紫癜中的应用 |
CN110256453A (zh) * | 2019-07-09 | 2019-09-20 | 江苏华豚药业有限公司 | 一种河豚毒素酯化物的制备方法 |
WO2022221963A1 (en) * | 2021-04-23 | 2022-10-27 | Wex Pharmaceuticals Inc. | Tetrodotoxin liquid formulations |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1568999A (zh) * | 2003-07-14 | 2005-01-26 | 南宁枫叶药业有限公司 | 稳定的医药用河豚毒素冷冻干燥制剂 |
CN101264063A (zh) * | 2007-03-15 | 2008-09-17 | 深圳市宏锦天生物科技有限公司 | 室温稳定的注射用河豚毒素制剂 |
-
2008
- 2008-04-07 CN CN 200810088914 patent/CN101554368B/zh not_active Expired - Fee Related
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107468646A (zh) * | 2017-08-22 | 2017-12-15 | 新乡医学院第附属医院 | 氨磷汀注射液在治疗小儿血小板减少性紫癜中的应用 |
CN110256453A (zh) * | 2019-07-09 | 2019-09-20 | 江苏华豚药业有限公司 | 一种河豚毒素酯化物的制备方法 |
WO2021003890A1 (zh) * | 2019-07-09 | 2021-01-14 | 赵继红 | 一种河豚毒素酯化物的制备方法 |
WO2022221963A1 (en) * | 2021-04-23 | 2022-10-27 | Wex Pharmaceuticals Inc. | Tetrodotoxin liquid formulations |
Also Published As
Publication number | Publication date |
---|---|
CN101554368B (zh) | 2013-06-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5530006A (en) | Rapamycin formulation for IV injection | |
US5516770A (en) | Rapamycin formulation for IV injection | |
US8222258B2 (en) | Stable pharmaceutical composition of freeze-dried tetrodoxin powder | |
ES2384451T3 (es) | Aplicación de levo-ornidazol en la preparación de un medicamento contra la infección de bacterias anaeróbicas . | |
US5616588A (en) | Rapamycin formulation for IV injection | |
CN101209255B (zh) | 连翘酯苷注射制剂及其制备方法 | |
AU2018204334A1 (en) | Improved daptomycin injectable formulation | |
CN109620799A (zh) | 稳定的盐酸溴己新液体制剂组合物及其制备方法 | |
CN101264063A (zh) | 室温稳定的注射用河豚毒素制剂 | |
CN101554368B (zh) | 一种室温稳定的注射用替曲朵辛组合物制剂 | |
CN101912361B (zh) | 一种盐酸头孢替安/无水碳酸钠药物组合物混悬注射剂及其新应用 | |
CN101756897A (zh) | 一种盐酸克林霉素注射剂及其制备方法 | |
CN103462910A (zh) | 一种注射用阿奇霉素组合物及其制备方法 | |
CN104688676A (zh) | 穿心莲内酯浓缩型液体组方及其医药用途 | |
CN105769756B (zh) | 一种富马酸西他沙星注射剂及其制备方法 | |
CN101003539A (zh) | 西林类化合物的氨丁三醇盐及其制备方法 | |
CN106176626B (zh) | L-丙氨酸-(14-冬凌草甲素)酯胃肠外用药物组合物 | |
CN103330932B (zh) | 一种米卡芬净或其盐的药物组合物 | |
CN1977828A (zh) | 一种注射针剂的制备及用途 | |
KR20240034229A (ko) | 피하 투여가 가능한 항생제 의약 조성물 | |
CN101837011A (zh) | 治疗糖尿病的药物组合物 | |
JPH04321625A (ja) | 抗腫瘍剤 | |
CN101366701A (zh) | N,n-二甲基甘氨酸-2,6-二异丙基苯酯盐类注射剂 | |
CN102552234A (zh) | 盐酸甲氯芬酯药物组合物及其冻干粉针剂的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
ASS | Succession or assignment of patent right |
Owner name: JIANGSU HONGJINTIAN PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: SHENZHEN HONGJINTIAN BIOTECHNOLOGY TECHNOLOGY CO., LTD. Effective date: 20100601 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 518067 UNIT 8, BUILDING 2, GUANGWUHUAYUAN, GONGYE 7TH ROAD, SHEKOU, NANSHAN DISTRICT, SHENZHEN CITY, GUANGDONG PROVINCE TO: 225300 NO.1, YAOCHENG AVENUE, TAIZHOU CITY, JIANGSU PROVINCE |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20100601 Address after: 225300 No. 1, drug City Avenue, Taizhou, Jiangsu Applicant after: Jiangsu Hongjintian Pharmaceutical Co.,Ltd. Address before: 2 8 units, 518067 garden, seven industrial road, Shekou, Guangdong, Shenzhen, Nanshan District, China Applicant before: Shenzhen Hongjintian Biotechnology Technology Co.,Ltd. |
|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130612 |